Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
peer reviewed ; The demographics of dyslipidaemia have changed towards a more complex atherogenic dyslipidaemia involving increased levels of LDL-C, in particular highly atherogenic small dense particles, hypertriglyceridaemia and low HDL, together with increased levels of markers of cardiovascular inflammation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower cardiovascular morbidity and mortality, but there still remains a high residual risk in dyslipidaemic patients, in particular with metabolic syndrome, type 2 diabetes, or low HDL levels. Fibrates have... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2008 |
Verlag/Hrsg.: |
Acta Medica Belgica
|
Schlagwörter: | Antilipemic Agents/therapeutic use / Atherosclerosis/epidemiology/etiology/prevention & control / Belgium/epidemiology / Clofibric Acid/therapeutic use / Dyslipidemias/complications/drug therapy/epidemiology / Humans / Morbidity / Risk Factors / Human health sciences / Pharmacy / pharmacology & toxicology / Endocrinology / metabolism & nutrition / Sciences de la santé humaine / Pharmacie / pharmacologie & toxicologie / Endocrinologie / métabolisme & nutrition |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26535717 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/9399 |